New Delhi, August 11, 2021: For the first quarter ended June 30, 2021, Zydus Cadila reported net profit of Rs.…
Ahmedabad September 18, 2020: Cadila Pharmaceuticals launches Obetocad in India, a generic version of Ocaliva® (Obeticholic Acid) primarily used for…
Ahmedabad, July 29, 2020: Ahmedabad-based Cadila Pharmaceuticals Limited recently announced the launch of biosimilar Rituximab for India market. Biosimilar Rituximab…
NEW DELHI, NOVEMBER-07-2019: The US Food and Drug Administration (FDA) has approved Sandoz’ biosimilar Ziextenzo (pegfilgrastim-bmez). The biosimilar pegfilgrastim has been…
Hyderabad, August 22, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched…
Pelgraz, – a pegylated G-CSF Biosimilar, is the latest addition to its established portfolio of over 30 oncology treatments across…
Mumbai, July 28, 2018: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY) announced today that it has launched Hervycta® (Trastuzumab), a…
Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce…
Bio and generic demand reflective of wider trends in the market – with overseas investments now prospering Amsterdam, March 21,…
Mumbai, March 08,2018: Pharma major Lupin today announced the signing of an agreement with CSIR-National Chemical Laboratory (CSIR-NCL, Pune) and…